Robrina Walker1, Thomas F Northrup2, John Tillitski1, Ira Bernstein3, Tracy L Greer1, Madhukar H Trivedi1. 1. a Department of Psychiatry , University of Texas Southwestern Medical Center , Dallas , Texas , USA. 2. b Department of Family and Community Medicine , The University of Texas Health Science Center at Houston, McGovern Medical School , Houston , Texas , USA. 3. c Department of Clinical Sciences , University of Texas Southwestern Medical Center , Dallas , Texas , USA.
Abstract
BACKGROUND:Cocaine and methamphetamine have similar withdrawal symptoms and many individuals concurrently use both substances; however, no measures concurrently assess withdrawal from multiple stimulants. OBJECTIVES: This study's aim was to explore the Stimulant Selective Severity Assessment (SSSA), a modified version of the Cocaine Selective Severity Assessment (CSSA), in a sample of stimulant users to determine if it can assess withdrawal symptoms in users of one or more stimulants. METHODS: Baseline data were analyzed from the STimulant Reduction Intervention using Dosed Exercise trial, a multisite randomized clinical trial that evaluated exercise versus health education on drug use outcomes in individuals with stimulant use disorders. Data were analyzed for internal consistency, construct validity, and scale dimensionality. RESULTS: Internal consistency for the full sample was good (α = 0.81; N = 302), with similar alphas in Cocaine (0.81; n = 177) and Cocaine/Other Stimulant (0.82; n = 92) groups, but with much lower alpha for the group without cocaine use (Other Stimulant, i.e., primarily methamphetamine, α = 0.66; n = 32). Support for construct validity was evidenced by significant positive correlations (r = 0.17 to 0.67) with measures of stimulant craving, depressive symptoms, and pain. Four factors were revealed. Conclusions/Importance: The Stimulant Selective Severity Assessment is a new measure that can be used to assess withdrawal symptoms in users of cocaine or cocaine plus methamphetamine, but it should not be administered to users of methamphetamine only.
RCT Entities:
BACKGROUND:Cocaine and methamphetamine have similar withdrawal symptoms and many individuals concurrently use both substances; however, no measures concurrently assess withdrawal from multiple stimulants. OBJECTIVES: This study's aim was to explore the Stimulant Selective Severity Assessment (SSSA), a modified version of the Cocaine Selective Severity Assessment (CSSA), in a sample of stimulant users to determine if it can assess withdrawal symptoms in users of one or more stimulants. METHODS: Baseline data were analyzed from the STimulant Reduction Intervention using Dosed Exercise trial, a multisite randomized clinical trial that evaluated exercise versus health education on drug use outcomes in individuals with stimulant use disorders. Data were analyzed for internal consistency, construct validity, and scale dimensionality. RESULTS: Internal consistency for the full sample was good (α = 0.81; N = 302), with similar alphas in Cocaine (0.81; n = 177) and Cocaine/Other Stimulant (0.82; n = 92) groups, but with much lower alpha for the group without cocaine use (Other Stimulant, i.e., primarily methamphetamine, α = 0.66; n = 32). Support for construct validity was evidenced by significant positive correlations (r = 0.17 to 0.67) with measures of stimulant craving, depressive symptoms, and pain. Four factors were revealed. Conclusions/Importance: The Stimulant Selective Severity Assessment is a new measure that can be used to assess withdrawal symptoms in users of cocaine or cocaine plus methamphetamine, but it should not be administered to users of methamphetamine only.
Authors: Madhukar H Trivedi; Tracy L Greer; Chad D Rethorst; Thomas Carmody; Bruce D Grannemann; Robrina Walker; Diane Warden; Kathy Shores-Wilson; Mark Stoutenberg; Neal Oden; Meredith Silverstein; Candace Hodgkins; Lee Love; Cindy Seamans; Angela Stotts; Trey Causey; Regina P Szucs-Reed; Paul Rinaldi; Hugh Myrick; Michele Straus; David Liu; Robert Lindblad; Timothy Church; Steven N Blair; Edward V Nunes Journal: J Clin Psychiatry Date: 2017 Sep/Oct Impact factor: 4.384
Authors: Thomas F Northrup; Charles Green; Robrina Walker; Tracy L Greer; Madhukar H Trivedi Journal: Addict Behav Date: 2014-11-25 Impact factor: 3.913
Authors: Edward F Pace-Schott; Peter T Morgan; Robert T Malison; Carl L Hart; Chris Edgar; Matthew Walker; Robert Stickgold Journal: Am J Drug Alcohol Abuse Date: 2008 Impact factor: 3.829
Authors: A John Rush; Madhukar H Trivedi; Hicham M Ibrahim; Thomas J Carmody; Bruce Arnow; Daniel N Klein; John C Markowitz; Philip T Ninan; Susan Kornstein; Rachel Manber; Michael E Thase; James H Kocsis; Martin B Keller Journal: Biol Psychiatry Date: 2003-09-01 Impact factor: 13.382
Authors: K M Kampman; J R Volpicelli; D E McGinnis; A I Alterman; R M Weinrieb; L D'Angelo; L E Epperson Journal: Addict Behav Date: 1998 Jul-Aug Impact factor: 3.913